

## **Product datasheet for TR306759**

## OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## **ALG14 Human shRNA Plasmid Kit (Locus ID 199857)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** ALG14 Human shRNA Plasmid Kit (Locus ID 199857)

**Locus ID:** 199857

Synonyms: CMS15; IDDEBF; MEPCA

**Vector:** pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

Components: ALG14 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

199857). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001305242, NM 144988, NR 131032, NM 144988.2, NM 144988.3, BC011706,

BC011706.2, NM 144988.4

UniProt ID: 096F25

Summary: This gene is a member of the glycosyltransferase 1 family. The encoded protein and ALG13

are thought to be subunits of UDP-GlcNAc transferase, which catalyzes the first two committed steps in endoplasmic reticulum N-linked glycosylation. Mutations in this gene have been linked to congenital myasthenic syndrome (CMSWTA). Alternatively spliced

transcript variants have been identified. [provided by RefSeq, Mar 2015]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).